Login to Your Account

Biopharma companies take advantage of welcoming IPO market

By Peter Winter

Monday, July 17, 2017

The biopharma sector has taken advantage of renewed interest from investors and welcoming financial markets, with 25 companies focused on developing new medicines successfully completing their IPOs on U.S., European and Australasia exchanges in the first half of the year – 20 percent more than the total who graduated to the public ranks this time last year. The amount raised to date is also almost twice as much generated from IPOs last year.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription